University of Connecticut School of Medicine, Farmington, CT.
Memorial Sloan Kettering Cancer Center, New York, NY.
Am Soc Clin Oncol Educ Book. 2024 Jun;44(3):e432462. doi: 10.1200/EDBK_432462.
Melanoma has long been a difficult malignancy to treat with low response rates to standard chemotherapies. In recent years, the use of immune checkpoint inhibitors have demonstrated promising results, paving the way for the use of the rapidly developing novel immune targeting therapies. In this review, we look beyond immune checkpoint inhibitor treatments and summarize several emerging treatment strategies for melanoma, including neoantigen vaccines, conventional antibody drug-conjugates, and bispecific T-cell engager therapies.
黑色素瘤一直是一种难以治疗的恶性肿瘤，对标准化疗的反应率较低。近年来，免疫检查点抑制剂的使用已经显示出了有希望的结果，为快速发展的新型免疫靶向治疗铺平了道路。在这篇综述中，我们超越了免疫检查点抑制剂的治疗方法，总结了几种黑色素瘤的新兴治疗策略，包括新抗原疫苗、传统抗体药物偶联物和双特异性 T 细胞衔接器疗法。
